Diurnal secretion of growth hormone, cortisol, and dehydroepiandrosterone in pre- and perimenopausal women with active rheumatoid arthritis: a pilot case-control study

Marc R Blackman, Ranganath Muniyappa, Mildred Wilson, Barbara E Moquin, Howard L Baldwin, Kelli A Wong, Christopher Snyder, Michael Magalnick, Shaan Alli, James Reynolds, Seth M Steinberg, Raphaela Goldbach-Mansky, Marc R Blackman, Ranganath Muniyappa, Mildred Wilson, Barbara E Moquin, Howard L Baldwin, Kelli A Wong, Christopher Snyder, Michael Magalnick, Shaan Alli, James Reynolds, Seth M Steinberg, Raphaela Goldbach-Mansky

Abstract

Rheumatoid arthritis (RA) is associated with neuroendocrine and immunologic dysfunction leading to rheumatoid cachexia. Although excess proinflammatory cytokines can decrease somatotropic axis activity, little is known about the effects of RA on growth hormone/insulin-like growth factor-1 (GH/IGF-I) axis function. We tested the hypothesis that patients with active RA exhibit decreased GH/IGF-I axis activity. To do so, we conducted a pilot case-control study at a clinical research center in 7 pre- and perimenopausal women with active RA and 10 age- and body mass index-matched healthy women. Participants underwent blood sampling every 20 minutes for 24 hours (8 a.m. to 8 a.m.), and sera were assayed for GH, cortisol, and dehydroepiandrosterone (DHEA). Sera obtained after overnight fasting were assayed for IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-3, C-reactive protein (CRP), interleukin-6 (IL-6), glucose, insulin, and lipids. Body composition and bone mineral density were evaluated by DEXA (dual emission x-ray absorptiometry) scans. In patients with RA, mean disease duration was 7.6 +/- 6.8 years, and erythrocyte sedimentation rate, CRP, and IL-6 were elevated. GH half-life was shorter than in control subjects (p = 0.0037), with no other significant group differences in GH deconvolution parameters or approximate entropy scores. IGF-I (p = 0.05) and IGFBP-3 (p = 0.058) were lower, whereas IGFBP-1 tended to be higher (p = 0.066), in patients with RA, with nonsignificantly increased 24-hour total GH production rates. There were no significant group differences in cortisol or DHEA secretion. Lean body mass was lower in patients with RA (p = 0.019), particularly in the legs (p = 0.01). Women with active RA exhibit a trend toward GH insensitivity and relatively diminished diurnal cortisol and DHEA secretion for their state of inflammation. Whether these changes contribute to rheumatoid cachexia remains to be determined.

Trial registration number: NCT00034060.

References

    1. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93:2379–2386.
    1. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001;44:1234–1236. doi: 10.1002/1529-0131(200106)44:6<1234::AID-ART213>;2-R.
    1. Riise T, Jacobsen BK, Gran JT, Haga HJ, Arnesen E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol. 2001;20:123–127. doi: 10.1007/PL00011191.
    1. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004;43:1219–1223. doi: 10.1093/rheumatology/keh321.
    1. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20–39. doi: 10.1210/er.14.1.20.
    1. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643–650.
    1. Templ E, Koeller M, Riedl M, Wagner O, Graninger W, Luger A. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Br J Rheumatol. 1996;35:350–356. doi: 10.1093/rheumatology/35.4.350.
    1. Masi AT, Aldag JC, Jacobs JW. Rheumatoid arthritis: neuroendocrine immune integrated physiopathogenetic perspectives and therapy. Rheum Dis Clin North Am. 2005;31:131–160, x. doi: 10.1016/j.rdc.2004.09.006.
    1. Demir H, Kelestimur F, Tunc M, Kirnap M, Ozugul Y. Hypothalamo-pituitary-adrenal axis and growth hormone axis in patients with rheumatoid arthritis. Scand J Rheumatol. 1999;28:41–46. doi: 10.1080/03009749950155779.
    1. Veldhuis JD, Johnson ML. Deconvolution analysis of hormone data. Methods Enzymol. 1992;210:539–575.
    1. Pincus S, Singer BH. Randomness and degrees of irregularity. Proc Natl Acad Sci USA. 1996;93:2083–2088. doi: 10.1073/pnas.93.5.2083.
    1. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Twenty-four-hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J Clin Endocrinol Metab. 1990;71:1616–1623.
    1. Denko CW, Malemud CJ. The serum growth hormone to somatostatin ratio is skewed upward in rheumatoid arthritis patients. Front Biosci. 2004;9:1660–1664. doi: 10.2741/1354.
    1. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum. 2005;35:24–34. doi: 10.1016/j.semarthrit.2005.03.001.
    1. Lemmey A, Maddison P, Breslin A, Cassar P, Hasso N, McCann R, Whellams E, Holly J. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J Rheumatol. 2001;28:29–34.
    1. Matsumoto T, Tsurumoto T. Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:352–353. doi: 10.1093/rheumatology/41.3.352.
    1. Rovensky J, Bakosova J, Koska J, Ksinantova L, Jezova D, Vigas M. Somatotropic, lactotropic and adrenocortical responses to insulin-induced hypoglycemia in patients with rheumatoid arthritis. Ann NY Acad Sci. 2002;966:263–270.
    1. Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. Rheumatology (Oxford) 2005;44:120–125. doi: 10.1093/rheumatology/keh421.
    1. Rall LC, Walsmith JM, Snydman L, Reichlin S, Veldhuis JD, Kehayias JJ, Abad LW, Lundgren NT, Roubenoff R. Cachexia in rheumatoid arthritis is not explained by decreased growth hormone secretion. Arthritis Rheum. 2002;46:2574–2577. doi: 10.1002/art.10714.
    1. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278:E967–976.
    1. Le Roith D, Scavo L, Butler A. What is the role of circulating IGF-I? Trends Endocrinol Metab. 2001;12:48–52. doi: 10.1016/S1043-2760(00)00349-0.
    1. Schaefer F, Baumann G, Haffner D, Faunt LM, Johnson ML, Mercado M, Ritz E, Mehls O, Veldhuis JD. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. J Clin Endocrinol Metab. 1996;81:22–31. doi: 10.1210/jc.81.1.22.
    1. Anders HJ, Rihl M, Loch O, Schattenkirchner M. Prediction of creatinine clearance from serum creatinine in patients with rheumatoid arthritis: comparison of six formulae and one nomogram. Clin Rheumatol. 2000;19:26–29. doi: 10.1007/s100670050006.
    1. Lim WH, Lim EM, McDonald S. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology (Carlton) 2006;11:250–256. doi: 10.1111/j.1440-1797.2006.00560.x.
    1. Rosenfeld RG, Hwa V. New molecular mechanisms of GH resistance. Eur J Endocrinol. 2004;151:S11–15. doi: 10.1530/eje.0.151S011.
    1. Baxter RC. Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15:421–434. doi: 10.1053/beem.2001.0161.
    1. Thissen JP, Verniers J. Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology. 1997;138:1078–1084. doi: 10.1210/en.138.3.1078.
    1. Frost RA, Lang CH. Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci. 2004;82(E-Suppl):E100–109.
    1. Picardi A, Gentilucci UV, Zardi EM, Caccavo D, Petitti T, Manfrini S, Pozzilli P, Afeltra A. TNF-alpha and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res. 2003;23:229–235. doi: 10.1089/107999003321829944.
    1. Benbassat CA, Lazarus DD, Cichy SB, Evans TM, Moldawer LL, Lowry SF, Unterman TG. Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro. Horm Metab Res. 1999;31:209–215.
    1. Nemet D, Eliakim A, Zaldivar F, Cooper DM. Effect of rhIL-6 infusion on GH-->IGF-I axis mediators in humans. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1663–1668.
    1. Harbuz MS, Jessop DS. Is there a defect in cortisol production in rheumatoid arthritis? Rheumatology (Oxford) 1999;38:298–302. doi: 10.1093/rheumatology/38.4.298.
    1. Cutolo M, Sulli A, Pizzorni C, Craviotto C, Straub RH. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann NY Acad Sci. 2003;992:107–117.
    1. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997;82:1279–1283. doi: 10.1210/jc.82.4.1279.
    1. Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 2002;46:654–662. doi: 10.1002/art.10177.
    1. Vogl D, Falk W, Dorner M, Scholmerich J, Straub RH. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. J Rheumatol. 2003;30:269–275.
    1. Straub RH, Weidler C, Demmel B, Herrmann M, Kees F, Schmidt M, Scholmerich J, Schedel J. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004;63:961–968. doi: 10.1136/ard.2003.014274.
    1. Cutolo M, Foppiani L, Prete C, Ballarino P, Sulli A, Villaggio B, Seriolo B, Giusti M, Accardo S. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol. 1999;26:282–288.
    1. Straub RH, Harle P, Yamana S, Matsuda T, Takasugi K, Kishimoto T, Nishimoto N. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1778–1785. doi: 10.1002/art.21826.
    1. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999;282:671–676. doi: 10.1001/jama.282.7.671.
    1. Rittmaster RS, Loriaux DL, Cutler GB., Jr Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. J Clin Endocrinol Metab. 1985;61:462–466.
    1. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690–1694. doi: 10.1210/jc.77.6.1690.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren